Drive Cost-Efficiencies with Real-World Evidence (RWE)
Pharmaceutical Companies today need post-approval data to demonstrate product value in an environment where costs are more tightly controlled than ever before. PAREXEL Access Real World Evidence Ecosystem helps clients plan at a portfolio level, providing greater strategic advantage and the ability to identify greatest cost-efficiency for evidence generation. Joshua Schultz, Corporate VP and Head of PAREXEL Access, explains that through our Real-World Evidence Ecosystem, we drive average cost savings of around 20% by combining multiple late-stage studies. PAREXEL Access has an integrated market access consultancy, supporting more than 200 HTA submissions, in 12 countries, and over 200 economic modeling programs.